Question-and-Answer Session
Operator
Thank you (Operator Instructions). Our first question will come from Phil Nadeau with Cowen and Company.
Phil Nadeau - Cowen and Co.
Good morning. Congratulations on the solid quarter and thanks for taking my questions.
Deborah Dunsire
Thank you.
Phil Nadeau - Cowen and Co.
My first question is for Marsha. Marsha, could you remind us what the price increases have been on VELCADE over the last 12 months?
Kyle Kuvalanka
Phil, we're going to have Christophe start out with that and then Marsha will wrap up.
Phil Nadeau - Cowen and Co.
Okay, thanks.
Christophe Bianchi
Good morning. The price increase we took for VELCADE in January this year was 2.5% and in July last year we took also a 2.5% price increase on VELCADE.
Phil Nadeau - Cowen and Co.
Okay. Perfect, thanks. And then my second question, Christophe, is also for you and that's the data presentations at ASCO. The slides made it seem like we were going to get survival data from the Phase III trial for VELCADE plus DOXIL at the meeting and I just wanted to confirm that that is in fact the case.
Kyle Kuvalanka
Phil, we're going to have Nancy answer that question.
Phil Nadeau - Cowen and Co.
Thanks.
Nancy Simonian
So as you know at ASH survival data was presented and I think we will see updated survival data at ASCO this year.
Phil Nadeau - Cowen and Co.
Okay, perfect. And last question is on indolent NHL. I know you said that the enrollment was going along as planned. Could you give us some idea of timelines there, when we might see data?
Kyle Kuvalanka
And once again we'll have Nancy answer that.
Nancy Simonian
Yes, well we have not really been specific but you know it's a large global trial with 600, 700 patients so it's--but it's moving along and we have a large reach in terms of the enrollment territory, so other than that we really have not been specific.
Phil Nadeau - Cowen and Co.
Okay, thank you.
Operator
We'll take our next question from May-Kin Ho with Goldman Sachs.
May-Kin Ho - Goldman Sachs
Hi, can you tell us a little bit about the market share that you have now in the various lines of therapy for multiple myeloma on VELCADE?
Kyle Kuvalanka
Good morning, May-Kin. We're going to have Christophe answer that question.
| TRANSCRIPT SPONSOR |
- To read the full transcript on Seeking Alpha, click here »
